Does COVID-19 increase tacrolimus levels in kidney transplant recipients?

J Clin Pharm Ther. 2022 May;47(5):707-708. doi: 10.1111/jcpt.13586. Epub 2021 Dec 23.

Authors

Divya Bajpai¹, Nikhil Saxena¹, Chintan Gandhi¹, Tulsi Modi¹, Sreyashi Bose¹, Satarupa Deb¹, Nikhil Rao¹, Kruteesh Kumar¹, Abhinav Katyal¹, Ankita Patil¹, Sayali Thakare¹, Atim E Pajai¹, Ashwathy Haridas², Vaibhav S Keskar³, Sunil Y Jawale⁴, Amar G Sultan⁵, Tukaram E Jamale¹

Affiliations

¹ Department of Nephrology, Seth G.S.M.C. and K.E.M. Hospital, Mumbai, India.
² Department of Nephrology, Apollo Hospital, Navi Mumbai, India.
³ Kimaya Kidney Care, Thane, India.
⁴ Yashwant Kidney Care, Pune, India.
⁵ Amardeep Kidney Care, Akola, India.

PMID: 34951043
DOI: 10.1111/jcpt.13586

No abstract available

Keywords: COVID-19; CYP3A5 genotype; Kidney transplantation; tacrolimus trough concentrations.

Publication types

Letter

MeSH terms

COVID-19*
Cytochrome P-450 CYP3A / genetics
Genotype
Humans
Immunosuppressive Agents / adverse effects
Kidney Transplantation*
Polymorphism, Single Nucleotide
Tacrolimus / therapeutic use
Transplant Recipients

Substances

Immunosuppressive Agents
Cytochrome P-450 CYP3A
Tacrolimus